luveltamab tazevibulin (STRO-002) - Sutro Biopharma
Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov) - Aug 27, 2024 - P2 | N=43 | Recruiting | Sponsor: Sutro Biopharma, Inc. | Not yet recruiting ➔ Recruiting 
Enrollment open • Metastases • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
http://clinicaltrials.gov/ct2/show/NCT06555263
 
Aug 27, 2024
 
Prev Next